Objective: This study aims to investigate the change in quality adjusted life-years (QALYs) after providing oncology pharmacist services to assess its impact on humanistic outcome.
Methods: It was a prospective, single-centered study conducted for a period of two years at Bharat cancer Hospital and Nirali memorial radiation center, Surat. Patients were
Journal of Oncology Pharmacy Practice. 2022;28(2):302-309. /
Khadela A, Bhikadiya V, Vyas B.
Purpose: This study aimed to assess the impact of the patient-centered prescription (PCP) model in medication adherence and effective prescribing in patients with multimorbidity.
Methods: Uncontrolled before–after study in an intermediate care facility in a mixed urban–rural district. Inpatients aged ≥ 65 years with multimorbidity exposed to polypharmacy before hospital admission were consecutively
Eur J Clin Pharmacol 2022; 78: 127–137. /
González-Bueno J, Sevilla-Sánchez D, Puigoriol-Juvanteny E. et al.
Background: National rates of COVID-19 infection and fatality have varied dramatically since the onset of the pandemic. Understanding the conditions associated with this cross-country variation is essential to guiding investment in more effective preparedness and response for future pandemics.
Methods: Daily SARS-CoV-2 infections and COVID-19 deaths for 177 countries and territories
Lancet. 2022 Feb 1. doi: 10.1016/S0140-6736(22)00172-6. Epub ahead of print. /
COVID-19 National Preparedness Collaborators
There is strong evidence for brain-related abnormalities in COVID-191-13. It remains unknown however whether the impact of SARS-CoV-2 infection can be detected in milder cases, and whether this can reveal possible mechanisms contributing to brain pathology. Here, we investigated brain changes in 785 UK Biobank participants (aged 51-81) imaged twice,
Nature 2022 Mar 7.doi: 10.1038/s41586-022-04569-5. /
Douaud G, Lee S, Alfaro-Almagro F, et al.
Evidence regarding the effectiveness of COVID-19 vaccine in patients with impaired immunity is limited. Initial observations suggest a lower humoral response in these patients. We evaluated the relative effectiveness of the mRNA BNT162b2 vaccine in patients with hematological neoplasms compared with matched controls. Data on patients with hematological neoplasms after
Blood 2022; 139 (10): 1439–1451. /
Mittelman M,Magen O, Barda N, et al.
Objectives: To assess how and to what extent adherence to medication is reported in pivotal clinical trials of oral cancer drugs.
Methods: All drugs authorised by the European Medicines Agency from 1 January 2014 to 31 December 2019 were considered for analysis. For each pivotal trial we extracted the journal of publication, phase
Eur J Hosp Pharm 2022 Jan 20. Epub ahead of print. doi: 10.1136/ejhpharm-2021-002998. /
Lasala R, Santoleri F, Romagnoli A, et al.
The COVID-19 pandemic has led health systems to increase the use of tools for monitoring and triaging patients remotely. In this systematic review, we aim to assess the effectiveness and safety of pulse oximetry in remote patient monitoring (RPM) of patients at home with COVID-19. We searched five databases (MEDLINE,
The Lancet Digital Health 2022; 4(4): e279 - e289. /
Alboksmaty et al.
Background: In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Whether overall survival would also be longer with ribociclib was
N Engl J Med 2022; 386:942-950. /
Hortobagyi GN, Stemmer SM, Burris HA, et al.
Background: Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in the United States are highly effective, breakthrough infections are occurring. Data are needed on the serial use of homologous boosters (same as the primary vaccine) and heterologous boosters (different from the primary vaccine) in
N Engl J Med 2022; 386:1046-1057 /
Atmar RL, Lyke KE, Deming ME, et al.
Rationale: Drug-drug interactions (DDIs) with oral antineoplastics (OAs) are of increasing concern given the rapid increase in OA approvals and use in cancer patients. A small pilot study of 20 DDIs with OAs showed significant variability in commonly used DDI screening databases in sensitivity of detecting potentially clinically relevant DDIs.
Journal of Oncology Pharmacy Practice. 2022;28(1):82-86. /
Bossaer JB, Eskens D, Gardner A.